{ "version": "2.2", "instance": { "evax20250806_6k.htm ex_848977.htm": { "nsprefix": "evax", "nsuri": "http://www.evaxion-biotech.com/20240630", "dts": { "schema": { "local": [ "evax-20250630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd", "https://xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "evax-20250630_cal.xml" ] }, "definitionLink": { "local": [ "evax-20250630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "evax-20250630_lab.xml" ] }, "presentationLink": { "local": [ "evax-20250630_pre.xml" ] }, "inline": { "local": [ "evax20250806_6k.htm", "ex_848977.htm" ] } }, "keyStandard": 127, "keyCustom": 33, "axisStandard": 15, "axisCustom": 0, "memberStandard": 17, "memberCustom": 23, "hidden": { "total": 31, "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 18, "http://www.evaxion-biotech.com/20240630": 7, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 139, "entityCount": 1, "segmentCount": 47, "elementCount": 270, "unitCount": 11, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 426, "http://xbrl.sec.gov/dei/2024": 14 }, "report": { "R1": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "evax20250806_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "evax20250806_6k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss", "longName": "001 - Statement - Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "d_2025-04-01_2025-06-30", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-04-01_2025-06-30", "name": "ifrs-full:Revenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position", "longName": "002 - Statement - Unaudited Condensed Consolidated Interim Statements of Financial Position", "shortName": "Unaudited Condensed Consolidated Interim Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2025-06-30", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-06-30", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit", "longName": "003 - Statement - Unaudited Condensed Consolidated Interim Statements of Changes in Equity (Deficit)", "shortName": "Unaudited Condensed Consolidated Interim Statements of Changes in Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "i_2023-12-31_ComponentsOfEquityAxis-IssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_ComponentsOfEquityAxis-SharePremiumMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R5": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "longName": "004 - Statement - Unaudited Condensed Consolidated Interim Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Interim Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:AdjustmentsForReconcileProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R6": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-1-general-company-information", "longName": "005 - Disclosure - Note 1 - General Company Information", "shortName": "Note 1 - General Company Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "evax:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "evax:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "longName": "006 - Disclosure - Note 2 - Liquidity and Going Concern Assessment", "shortName": "Note 2 - Liquidity and Going Concern Assessment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "shortName": "Note 3 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-4-significant-accounting-judgements-estimates-and-assumptions", "longName": "008 - Disclosure - Note 4 - Significant Accounting Judgements, Estimates, and Assumptions", "shortName": "Note 4 - Significant Accounting Judgements, Estimates, and Assumptions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "longName": "009 - Disclosure - Note 5 - Revenue", "shortName": "Note 5 - Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "longName": "010 - Disclosure - Note 6 - Financial Instruments and Risk Management", "shortName": "Note 6 - Financial Instruments and Risk Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "longName": "011 - Disclosure - Note 7 - Borrowings", "shortName": "Note 7 - Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "longName": "012 - Disclosure - Note 8 - Share-based Payments", "shortName": "Note 8 - Share-based Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses", "longName": "013 - Disclosure - Note 9 - Financial Income and Expenses", "shortName": "Note 9 - Financial Income and Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "longName": "014 - Disclosure - Note 10 - Capital Structure and Financial Matters", "shortName": "Note 10 - Capital Structure and Financial Matters", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-11-commitments-and-contingencies", "longName": "015 - Disclosure - Note 11 - Commitments and Contingencies", "shortName": "Note 11 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "longName": "016 - Disclosure - Note 12 - Events After the Reporting Period", "shortName": "Note 12 - Events After the Reporting Period", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies", "longName": "017 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables", "longName": "018 - Disclosure - Note 6 - Financial Instruments and Risk Management (Tables)", "shortName": "Note 6 - Financial Instruments and Risk Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-tables", "longName": "019 - Disclosure - Note 7 - Borrowings (Tables)", "shortName": "Note 7 - Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables", "longName": "020 - Disclosure - Note 8 - Share-based Payments (Tables)", "shortName": "Note 8 - Share-based Payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-tables", "longName": "021 - Disclosure - Note 9 - Financial Income and Expenses (Tables)", "shortName": "Note 9 - Financial Income and Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "evax:FinancialIncomeAndExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "evax:FinancialIncomeAndExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-tables", "longName": "022 - Disclosure - Note 10 - Capital Structure and Financial Matters (Tables)", "shortName": "Note 10 - Capital Structure and Financial Matters (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-06-30", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "longName": "023 - Disclosure - Note 2 - Liquidity and Going Concern Assessment (Details Textual)", "shortName": "Note 2 - Liquidity and Going Concern Assessment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "d_2025-01-31_2025-01-31", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-01-17", "name": "evax:DecreaseInSharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R25": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "longName": "024 - Disclosure - Note 5 - Revenue (Details Textual)", "shortName": "Note 5 - Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "i_2025-06-30", "name": "evax:Grant", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-04-01_2025-06-30_CounterpartiesAxis-MsdMember", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R26": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "longName": "025 - Disclosure - Note 6 - Financial Instruments and Risk Management (Details Textual)", "shortName": "Note 6 - Financial Instruments and Risk Management (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "i_2025-06-30", "name": "ifrs-full:ParValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfLiquidityRiskExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-10-03_2024-10-03_CounterpartiesAxis-EibWarrantsMember", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R27": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "longName": "026 - Disclosure - Note 6 - Financial Instruments and Risk Management - Disclosure of Fair Value Measurements of Liabilities (Details)", "shortName": "Note 6 - Financial Instruments and Risk Management - Disclosure of Fair Value Measurements of Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "i_2025-06-30_LevelsOfFairValueHierarchyAxis-Level1OfFairValueHierarchyMember_MeasurementAxis-RecurringFairValueMeasurementMember", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-06-30_LevelsOfFairValueHierarchyAxis-Level1OfFairValueHierarchyMember_MeasurementAxis-RecurringFairValueMeasurementMember", "name": "ifrs-full:FinancialLiabilitiesAtFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "longName": "027 - Disclosure - Note 6 - Financial Instruments and Risk Management - Schedule of Warrant Liabilities (Details)", "shortName": "Note 6 - Financial Instruments and Risk Management - Schedule of Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "i_2024-12-31", "name": "ifrs-full:Liabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_ClassesOfLiabilitiesAxis-The2025InvestorWarrantsMember", "name": "ifrs-full:Liabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R29": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "longName": "028 - Disclosure - Note 7 - Borrowings (Details Textual)", "shortName": "Note 7 - Borrowings (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2025-06-30", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2020-10-01_2020-10-31_BorrowingsByNameAxis-LoanFromLessorMember", "name": "evax:LeaseArea", "unitRef": "SquareMetre", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R30": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details", "longName": "029 - Disclosure - Note 7 - Borrowings - Schedule of Borrowings (Details)", "shortName": "Note 7 - Borrowings - Schedule of Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "i_2025-06-30", "name": "ifrs-full:Borrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-06-30", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R31": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "longName": "030 - Disclosure - Note 8 - Share-based Payments (Details Textual)", "shortName": "Note 8 - Share-based Payments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "d_2020-01-01_2020-12-31_TypesOfSharebasedPaymentArrangementsAxis-WarrantsMember", "name": "evax:ShareBasedCompensationVestingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2020-01-01_2020-12-31_TypesOfSharebasedPaymentArrangementsAxis-WarrantsMember", "name": "evax:ShareBasedCompensationVestingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details", "longName": "031 - Disclosure - Note 8 - Share-based Payments - Warrant Activity (Details)", "shortName": "Note 8 - Share-based Payments - Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2024-12-31_TypesOfSharebasedPaymentArrangementsAxis-WarrantsMember", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_TypesOfSharebasedPaymentArrangementsAxis-WarrantsMember", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details", "longName": "032 - Disclosure - Note 8 - Share-based Compensation - Warrant Assumptions (Details)", "shortName": "Note 8 - Share-based Compensation - Warrant Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2025-06-30_ClassesOfEntitysOwnEquityInstrumentsAxis-WarrantsMember_UnobservableInputsAxis-HistoricalVolatilityForSharesMeasurementInputMember", "name": "ifrs-full:SignificantUnobservableInputEntitysOwnEquityInstruments", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-06-30_ClassesOfEntitysOwnEquityInstrumentsAxis-WarrantsMember_UnobservableInputsAxis-HistoricalVolatilityForSharesMeasurementInputMember", "name": "ifrs-full:SignificantUnobservableInputEntitysOwnEquityInstruments", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "longName": "033 - Disclosure - Note 9 - Financial Income and Expenses - Components of Financial Income and Expenses (Details)", "shortName": "Note 9 - Financial Income and Expenses - Components of Financial Income and Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "d_2025-04-01_2025-06-30", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "evax:FinancialIncomeAndExpensesTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-04-01_2025-06-30", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "evax:FinancialIncomeAndExpensesTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "longName": "034 - Disclosure - Note 10 - Capital Structure and Financial Matters (Details Textual)", "shortName": "Note 10 - Capital Structure and Financial Matters (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2025-01-31", "name": "ifrs-full:ParValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-01-17_ClassesOfShareCapitalAxis-OrdinarySharesMember", "name": "evax:IncreaseDecreaseInParValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R36": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "longName": "035 - Disclosure - Note 10 - Capital Structure and Financial Matters - Schedule of Share Capital (Details)", "shortName": "Note 10 - Capital Structure and Financial Matters - Schedule of Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "i_2025-01-17", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-02-05_2025-02-05_ClassesOfShareCapitalAxis-OrdinarySharesMember_ComponentsOfEquityAxis-IssuedCapitalMember", "name": "evax:IncreaseDecreaseInNumberOfSharesOutstandingFromWarrantExercises", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "unique": true } }, "R37": { "role": "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "longName": "036 - Disclosure - Note 12 - Events After the Reporting Period (Details Textual)", "shortName": "Note 12 - Events After the Reporting Period (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "d_2025-07-11_2025-07-11_NonadjustingEventsAfterReportingPeriodAxis-DebtConversionMember", "name": "ifrs-full:ChangesInEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-07-11_2025-07-11_NonadjustingEventsAfterReportingPeriodAxis-DebtConversionMember", "name": "ifrs-full:ChangesInEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "ex_848977.htm", "first": true, "unique": true } } }, "tag": { "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities", "crdr": "debit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities", "terseLabel": "Adjustments for increase (decrease) in derivative financial liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]" } } }, "auth_ref": [ "r145" ] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments for non-cash items" } }, "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r47" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "evax_AmericanDepositoryShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "AmericanDepositoryShareMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "American depository share [member]", "documentation": "Represents an American Depository Share (ADS)." } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_Assets", "totalLabel": "TOTAL ASSETS" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r11", "r70", "r71", "r76", "r103", "r106" ] }, "evax_AtTheMarketSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "AtTheMarketSharesMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "At the market shares [member]", "documentation": "Represents at the market shares." } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Loss per share \u2013 basic and diluted (in dollars per share)" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r38", "r39" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "Total Borrowings", "terseLabel": "Total borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r149" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r149" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_BorrowingsInterestRate", "terseLabel": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r149" ] }, "evax_BorrowingsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "BorrowingsTerm", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_BorrowingsTerm", "terseLabel": "Borrowings, term (Year)", "documentation": "Represents the term of borrowings." } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CapitalReserve", "terseLabel": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at January 1", "periodEndLabel": "Cash and cash equivalents at June 30" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r8", "r53", "r67" ] }, "evax_CashFlowsFromChangesInWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "CashFlowsFromChangesInWorkingCapitalAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flow from changes in working capital:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "totalLabel": "Net cash provided by/ (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r45", "r54" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r45", "r54" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]" } } }, "auth_ref": [ "r45", "r54" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "totalLabel": "Cash flow from operating activities before changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r125", "r145" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ChangesInEquity", "terseLabel": "Increase (decrease) in equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_ChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Changes in equity [abstract]" } } }, "auth_ref": [] }, "evax_ClassOfWarrantExercisePriceOfWarrants": { "xbrltype": "perShareItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ClassOfWarrantExercisePriceOfWarrants", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_ClassOfWarrantExercisePriceOfWarrants", "terseLabel": "Class of warrant, exercise price of warrants (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants." } } }, "auth_ref": [] }, "evax_ClassOfWarrantOrRightExercisedInPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ClassOfWarrantOrRightExercisedInPeriodValue", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "terseLabel": "Class of warrant or right exercised in period, value", "documentation": "The value of the warrant or right exercised during the period." } } }, "auth_ref": [] }, "evax_ClassOfWarrantTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ClassOfWarrantTerm", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_ClassOfWarrantTerm", "terseLabel": "Class of warrant, term (Year)", "documentation": "Period of expiration of warrants." } } }, "auth_ref": [] }, "evax_ClassOfWarrantsExercisablePercentageOfAds": { "xbrltype": "percentItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ClassOfWarrantsExercisablePercentageOfAds", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_ClassOfWarrantsExercisablePercentageOfAds", "terseLabel": "Class of warrants, exercisable, percentage of ADs", "documentation": "Percentage of ADs issued for exercisable shares of warrants." } } }, "auth_ref": [] }, "evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ClassOfWarrantsOrRightsForfeitedInPeriodValue", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Forfeited warrants", "documentation": "The value of the warrants that were forfeited during the period." } } }, "auth_ref": [] }, "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfEntitysOwnEquityInstrumentsAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Classes of entity's own equity instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_ClassesOfEntitysOwnEquityInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfEntitysOwnEquityInstrumentsDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Classes of entity's own equity instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for equity instruments issued by the entity. It also represents the standard value for the 'Classes of entity's own equity instruments' axis if no other member is used." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_ClassesOfLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_ClassesOfLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfLiabilitiesDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Classes of liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "auth_ref": [ "r77" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r18" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r18" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that may be reclassified to profit or loss in subsequent periods:" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossBeforeTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossBeforeTaxAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ComprehensiveIncome", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r0", "r22", "r57", "r59", "r64", "r126" ] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "totalLabel": "Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r0", "r24" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r99" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CurrentAssets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r12", "r60", "r126" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "negatedLabel": "Less: Borrowings, current portion" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r138" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Derivative liability" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r138" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Lease liabilities, current" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r81" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_CurrentLiabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r13", "r62", "r126" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPortionOfLongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentPortionOfLongtermBorrowings", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Borrowings, current" } }, "en": { "role": { "documentation": "The current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r138" ] }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Prepayments and other receivables" } }, "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } } }, "auth_ref": [ "r138" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Tax receivables, current" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r10" ] }, "ifrs-full_CurrentTaxAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTaxAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Tax receivables, non-current" } }, "en": { "role": { "documentation": "The non-current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r10" ] }, "evax_DebtConversionAmountConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "DebtConversionAmountConverted", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_DebtConversionAmountConverted", "terseLabel": "Debt conversion, amount converted", "documentation": "The value debt being converted." } } }, "auth_ref": [] }, "evax_DebtConversionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "DebtConversionMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual" ], "lang": { "en-us": { "role": { "label": "Debt conversion [member]", "documentation": "the debt conversion." } } }, "auth_ref": [] }, "evax_DecreaseInFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "DecreaseInFairValueMeasurementLiabilities", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "evax_DecreaseInFairValueMeasurementLiabilities", "negatedTerseLabel": "Change in fair value of derivative liability", "documentation": "The decrease in the fair value measurement of liabilities." } } }, "auth_ref": [] }, "evax_DecreaseInSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "DecreaseInSharesAuthorized", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_DecreaseInSharesAuthorized", "terseLabel": "Decrease in shares authorized (in shares)", "documentation": "The decrease in the amount of shares authorized." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]" } }, "en": { "role": { "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have." } } }, "auth_ref": [ "r55" ] }, "evax_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivitiesTextBlock", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-1-general-company-information" ], "lang": { "en-us": { "role": { "label": "Description of nature of entity's operations and principal activities [text block]", "documentation": "The description of the nature of the entity's operations and principal activities." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-4-significant-accounting-judgements-estimates-and-assumptions" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]" } }, "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings" ], "lang": { "en-us": { "role": { "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r18" ] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-11-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r149" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r95", "r96", "r97" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]" } }, "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r89" ] }, "ifrs-full_DisclosureOfLiquidityRiskExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfLiquidityRiskExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment" ], "lang": { "en-us": { "role": { "label": "Disclosure of liquidity risk [text block]" } }, "en": { "role": { "documentation": "The disclosure of liquidity risk. [Refer: Liquidity risk [member]]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [text block]" } }, "en": { "role": { "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]" } } }, "auth_ref": [ "r30" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue" ], "lang": { "en-us": { "role": { "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r19" ] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments" ], "lang": { "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r84" ] }, "evax_DisclosureOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Discloure of Significant Accounting Policies" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Exchange rate adjustments on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r48", "r49" ] }, "evax_EibLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "EibLoanMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "EIB loan [member]", "documentation": "Relating to EIB loan." } } }, "auth_ref": [] }, "evax_EibLoanTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "EibLoanTrancheOneMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "EIB loan tranche one [member]", "documentation": "Relating to EIB loan tranche one." } } }, "auth_ref": [] }, "evax_EibWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "EibWarrantsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "EIB warrants [member]", "documentation": "Relating to the EIB warrants." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r133" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information", "http://www.evaxion-biotech.com/20250630/role/statement-note-1-general-company-information", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-11-commitments-and-contingencies", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.evaxion-biotech.com/20250630/role/statement-note-4-significant-accounting-judgements-estimates-and-assumptions", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-tables", "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "terseLabel": "Entity Listing, Depository Receipt Ratio", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r133" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "verboseLabel": "Share capital", "label": "ifrs-full_Equity", "terseLabel": "Equity", "totalLabel": "Total equity (deficit)", "periodStartLabel": "Equity", "periodEndLabel": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r11", "r15", "r56", "r58", "r70", "r71", "r76" ] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_EquityAndLiabilities", "totalLabel": "TOTAL EQUITY AND LIABILITIES" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r11" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "EQUITY (DEFICIT) AND LIABILITIES" } } }, "auth_ref": [] }, "evax_ExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ExpectedTermMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected term [member]", "documentation": "Relating to expected term." } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "terseLabel": "Expense from share-based payment transactions" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r91" ] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 0.0 }, "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_FinanceCosts", "negatedLabel": "Finance expenses", "negatedTotalLabel": "Total financial expenses" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r26" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 0.0 }, "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Finance income", "totalLabel": "Total financial income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r141" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_FinanceIncomeCost", "totalLabel": "Net financial items" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r141" ] }, "evax_FinancialIncomeAndExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "FinancialIncomeAndExpensesTextBlock", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-tables" ], "lang": { "en-us": { "role": { "label": "Financial income and expenses [text block]", "documentation": "Schedule of financial income and expenses." } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, amortized cost" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r94" ] }, "ifrs-full_FixedInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FixedInterestRateMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Fixed interest rate [member]" } }, "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_GainsLossesOnFinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GainsLossesOnFinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_GainsLossesOnFinancialLiabilitiesAtAmortisedCost", "terseLabel": "Gains (losses) on financial liabilities at amortised cost" } }, "en": { "role": { "documentation": "The gains (losses) on financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r93" ] }, "ifrs-full_GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementLiabilities", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Reclassification of derivative liability", "terseLabel": "Gains (losses) recognised in other comprehensive income including exchange differences, fair value measurement, liabilities" } }, "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in other comprehensive income on the fair value measurement of liabilities. [Refer: At fair value [member]; Other comprehensive income]" } } }, "auth_ref": [ "r74" ] }, "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Remeasurement of derivative liability", "terseLabel": "Remeasurement of warrant liability" } }, "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r73" ] }, "evax_GainsRecognisedInProfitOrLossIncludingExchangeDifferencesFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "GainsRecognisedInProfitOrLossIncludingExchangeDifferencesFairValueMeasurementLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "evax_GainsRecognisedInProfitOrLossIncludingExchangeDifferencesFairValueMeasurementLiabilities", "terseLabel": "Remeasurement of warrant obligation", "documentation": "The gains including exchange differences recognised in profit or loss on the fair value measurement of liabilities" } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_GeneralAndAdministrativeExpense", "negatedLabel": "General and administrative" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r136" ] }, "evax_GlobalGrowthHoldingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "GlobalGrowthHoldingLimitedMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "Global Growth Holding Limited [member]", "documentation": "Relating to Global Growth Holding Limited." } } }, "auth_ref": [] }, "evax_Grant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "Grant", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_Grant", "terseLabel": "Grant", "documentation": "Amount of grant." } } }, "auth_ref": [] }, "evax_GrantsReceivableNoncurrent1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "GrantsReceivableNoncurrent1", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Government grants receivable", "documentation": "Represents the amount of grants receivable classified as noncurrent." } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Historical volatility for shares, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r127" ] }, "evax_HorsholmDenmarkLaboratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "HorsholmDenmarkLaboratorySpaceMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Horsholm, Denmark laboratory space [member]", "documentation": "Relating to laboratory space in Horsholm, Denmark." } } }, "auth_ref": [] }, "evax_HorsholmDenmarkOfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "HorsholmDenmarkOfficeSpaceMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Horsholm, Denmark office space [member]", "documentation": "Relating to the office space in Horsholm, Denmark." } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_IncomeTaxExpenseContinuingOperations", "negatedLabel": "Income tax benefit" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r27", "r31", "r32", "r33", "r37", "r69", "r102" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "negatedLabel": "Income taxes (paid)/received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r51", "r120" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "totalLabel": "Net increase/ (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r53" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued", "terseLabel": "Increase (decrease) in number of ordinary shares issued (in shares)" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r136" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital increase at January 24, 2025 (JonesTrading sales agreement) (in shares)", "label": "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding", "terseLabel": "Increase (decrease) in number of shares outstanding (in shares)" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r17" ] }, "evax_IncreaseDecreaseInNumberOfSharesOutstandingFromWarrantExercises": { "xbrltype": "sharesItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "IncreaseDecreaseInNumberOfSharesOutstandingFromWarrantExercises", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital increase at January 8, 2025 (exercised warrants) (in shares)", "label": "evax_IncreaseDecreaseInNumberOfSharesOutstandingFromWarrantExercises", "documentation": "The increase (decrease) in the number of shares outstanding from warrant exercises. [Refer: Number of shares outstanding]" } } }, "auth_ref": [] }, "evax_IncreaseDecreaseInParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "IncreaseDecreaseInParValuePerShare", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_IncreaseDecreaseInParValuePerShare", "terseLabel": "Increase (decrease) in par value per share (in dollars per share)", "documentation": "The increase (decrease) in the par value per share" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_IncreaseDecreaseInWorkingCapital", "negatedLabel": "Changes in net working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r145" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital increase, exercise of warrants", "label": "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r135" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Share-based compensation" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r3" ] }, "evax_IncreaseInFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "IncreaseInFairValueMeasurementLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "evax_IncreaseInFairValueMeasurementLiabilities", "terseLabel": "Change in fair value of derivative liability", "documentation": "The increase decrease in the fair value measurement of liabilities." } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_InterestExpense", "negatedTerseLabel": "Interest expenses" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r68", "r101", "r108" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_InterestExpenseOnLeaseLiabilities", "negatedTerseLabel": "Interest expenses, lease liabilities" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r82" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_InterestIncomeOnCashAndCashEquivalents", "terseLabel": "Interest income, bank" } }, "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } } }, "auth_ref": [ "r136" ] }, "ifrs-full_InterestIncomeOnOtherFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestIncomeOnOtherFinancialAssets", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_InterestIncomeOnOtherFinancialAssets", "terseLabel": "Interest income, other" } }, "en": { "role": { "documentation": "The amount of interest income on other financial assets. [Refer: Interest income; Other financial assets]" } } }, "auth_ref": [ "r136" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_InterestPaidClassifiedAsOperatingActivities", "negatedLabel": "Interest paid" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Interest received" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as operating activities." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Capital decrease at January 17, 2025", "label": "Issuance of shares for cash", "terseLabel": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r3" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_IssuesFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuesFairValueMeasurementLiabilities", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Initial recognition of derivative liability", "terseLabel": "Issues, fair value measurement, liabilities" } }, "en": { "role": { "documentation": "The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r75" ] }, "evax_JonesTradingInstitutionalServicesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "JonesTradingInstitutionalServicesLLCMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "JonesTrading Institutional Services LLC [member]", "documentation": "Represents JonesTrading Institutional Services LLC." } } }, "auth_ref": [] }, "evax_JonestradingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "JonestradingSalesAgreementMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "JonesTrading sales agreement [member]", "documentation": "Represents the JonesTrading Sales Agreement." } } }, "auth_ref": [] }, "evax_LeaseArea": { "xbrltype": "areaItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "LeaseArea", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_LeaseArea", "terseLabel": "Lease, area (Square Metre)", "documentation": "Represents the area of a leased property." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-document-and-entity-information", "http://www.evaxion-biotech.com/20250630/role/statement-note-1-general-company-information", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-11-commitments-and-contingencies", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.evaxion-biotech.com/20250630/role/statement-note-4-significant-accounting-judgements-estimates-and-assumptions", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-tables", "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r35", "r40", "r41", "r71" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r40", "r41", "r71" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r40", "r41", "r71" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r35", "r71" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r35", "r71" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_Liabilities", "totalLabel": "Total liabilities", "periodStartLabel": "Carrying amount at January 1, 2025", "periodEndLabel": "Carrying amount at June 30, 2025" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r11", "r70", "r71", "r76", "r103", "r107" ] }, "evax_LoanFromLessorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "LoanFromLessorMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details" ], "lang": { "en-us": { "role": { "label": "Loan from lessor [member]", "documentation": "Relating to loan from lessor." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Total Borrowings, non-current portion" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r138" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Leasehold deposits, non-current" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r138" ] }, "evax_LossesRecognisedInProfitOrLossIncludingExchangeDifferencesFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "LossesRecognisedInProfitOrLossIncludingExchangeDifferencesFairValueMeasurementLiabilities", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "evax_LossesRecognisedInProfitOrLossIncludingExchangeDifferencesFairValueMeasurementLiabilities", "negatedTerseLabel": "Remeasurement of warrant obligation", "documentation": "The losses including exchange differences recognised in profit or loss on the fair value measurement of liabilities" } } }, "auth_ref": [] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "Major ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r118" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r43", "r44", "r70" ] }, "ifrs-full_MeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MeasurementDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Measurement [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r43", "r44", "r70" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [] }, "evax_MsdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "MsdMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "MSD [member]", "documentation": "Represents MSD, tradename of Merck & Co., Inc." } } }, "auth_ref": [] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NetForeignExchangeGain", "terseLabel": "Foreign exchange gains" } }, "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r137", "r142" ] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NetForeignExchangeLoss", "negatedTerseLabel": "Foreign exchange losses" } }, "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r137", "r142" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r30" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r30" ] }, "evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability", "negatedLabel": "Non-cash effect from issue of investor warrants classified as derivative liability", "documentation": "Represents the non-cash effect from issue of investor warrants classified as derivative liability." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NoncurrentAssets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r12", "r61", "r126" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Lease liabilities, non-current" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r81" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NoncurrentLiabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r13", "r63", "r126" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentProvisions", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r9" ] }, "evax_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "evax_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NotionalAmount", "terseLabel": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r136" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Warrants granted", "terseLabel": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r90", "r147" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "negatedLabel": "Warrants forfeited" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "periodStartLabel": "Warrants granted", "periodEndLabel": "Warrants outstanding" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_NumberOfSharesIssued", "terseLabel": "Number of shares issued (in shares)" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r135" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Share capital, shares (in shares)", "label": "ifrs-full_NumberOfSharesOutstanding", "terseLabel": "Number of shares outstanding (in shares)" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r17" ] }, "evax_OrdinarySharesIssuanceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "OrdinarySharesIssuanceOneMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, issuance one [member]", "documentation": "Represents issuance one of ordinary shares." } } }, "auth_ref": [] }, "evax_OrdinarySharesIssuanceTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "OrdinarySharesIssuanceTwoMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, issuance two [member]", "documentation": "Represents issuance two of ordinary shares." } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r140" ] }, "evax_OrdinaryWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "OrdinaryWarrantsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual" ], "lang": { "en-us": { "role": { "label": "Ordinary warrants [member]", "documentation": "Represents ordinary warrants." } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "totalLabel": "Other comprehensive income for the period, net of tax" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r2", "r21", "r28", "r66" ] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxCashFlowHedges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxCashFlowHedges", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to cash flow hedges. [Refer: Cash flow hedges [member]; Other comprehensive income, before tax]" } } }, "auth_ref": [ "r14", "r29" ] }, "ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Exchange differences on currency translation to presentation currency" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]" } } }, "auth_ref": [ "r14", "r29" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Other payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r116" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ParValuePerShare", "terseLabel": "Par value per share (in dollars per share)" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r16" ] }, "evax_PaymentInKindInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PaymentInKindInterestRateMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Payment in kind interest rate [member]", "documentation": "Relating to payment in kind interest rate." } } }, "auth_ref": [] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "ifrs-full_PaymentsForShareIssueCosts", "negatedLabel": "Transaction costs related to issuance of shares" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r144" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "negatedLabel": "Leasing installments" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r124" ] }, "evax_PercentageOfTotalEquity": { "xbrltype": "percentItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PercentageOfTotalEquity", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_PercentageOfTotalEquity", "terseLabel": "Percentage of total equity", "documentation": "Represents the percentage of total equity." } } }, "auth_ref": [] }, "evax_PremiumOfSharePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PremiumOfSharePrice", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_PremiumOfSharePrice", "terseLabel": "Premium of share price", "documentation": "Represents the percent of premium on the share price." } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities", "terseLabel": "Proceeds from borrowings, classified as financing activities" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r122" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of shares and exercise of warrants", "terseLabel": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r121" ] }, "evax_ProceedsFromPaymentsForFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ProceedsFromPaymentsForFinancialAssets", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Payment of non-current financial assets \u2013 leasehold deposits", "documentation": "Represents the amount of cash inflow (outflow) from financial assets." } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent", "weight": 1.0, "order": 0.0 }, "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss for the period", "label": "Net loss for the period", "totalLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r1", "r20", "r46", "r57", "r59", "r103", "r105", "r126", "r130" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ProfitLossAttributableToOwnersOfParent", "totalLabel": "Net loss attributable to shareholders of Evaxion Biotech A/S" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r23" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ProfitLossBeforeTax", "totalLabel": "Net loss before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r92", "r112", "r113", "r131", "r132" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ProfitLossFromOperatingActivities", "totalLabel": "Operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r119", "r141" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r7", "r34" ] }, "evax_PublicOfferingSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PublicOfferingSharesMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "Public offering shares [member]", "documentation": "Represents public offering shares." } } }, "auth_ref": [] }, "evax_PurchaseAgreementCommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PurchaseAgreementCommitmentFee", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_PurchaseAgreementCommitmentFee", "terseLabel": "Purchase agreement, commitment fee", "documentation": "Represents the commitment fee for a purchase agreement." } } }, "auth_ref": [] }, "evax_PurchaseAgreementMaximumAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PurchaseAgreementMaximumAggregateAmount", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_PurchaseAgreementMaximumAggregateAmount", "terseLabel": "Purchase agreement, maximum aggregate amount", "documentation": "Represents the maximum aggregate amount of stock available to be issued as part of a purchase agreement." } } }, "auth_ref": [] }, "evax_PurchaseAgreementMaximumRequiredSinglePurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "PurchaseAgreementMaximumRequiredSinglePurchaseAmount", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_PurchaseAgreementMaximumRequiredSinglePurchaseAmount", "terseLabel": "Purchase agreement, maximum required single purchase amount", "documentation": "Represents the maximum required single purchase amount as part of a purchase agreement." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r52", "r78", "r83", "r87", "r128", "r129", "r149" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r52", "r78", "r83", "r87", "r128", "r129", "r149" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "auth_ref": [] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RecurringFairValueMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RecurringFairValueMeasurementMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Recurring fair value measurement [member]" } }, "en": { "role": { "documentation": "This member stands for fair value measurements which other IFRSs require or permit in the statement of financial position at the end of each reporting period. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "negatedLabel": "Repayment of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "ifrs-full_ResearchAndDevelopmentExpense", "negatedLabel": "Research and development" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r36", "r114" ] }, "ifrs-full_ReserveOfSharebasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReserveOfSharebasedPaymentsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Reserve of share-based payments [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from share-based payments." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r116", "r117" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r5", "r114" ] }, "evax_RevaluationOfStockBasedCompensationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "RevaluationOfStockBasedCompensationReserve", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Revaluation SBC reserve", "documentation": "The amount revaluated for the stock based compensation reserve." } } }, "auth_ref": [] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r25", "r65", "r92", "r100", "r104", "r109", "r110", "r111", "r112", "r113", "r126" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "ifrs-full_RevenueFromContractsWithCustomers", "terseLabel": "Revenue from contracts with customers" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r79", "r80" ] }, "evax_RiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "RiskFreeInterestRateMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate [member]", "documentation": "Relating to the risk free interest rate." } } }, "auth_ref": [] }, "evax_ShareBasedCompensationVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "ShareBasedCompensationVestingPeriod", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_ShareBasedCompensationVestingPeriod", "terseLabel": "Share based compensation, vesting period (Month)", "documentation": "Represents the vesting period of a share based compensation award." } } }, "auth_ref": [] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r5" ] }, "evax_SharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "SharePriceMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Share price [member]", "documentation": "Relating to share price." } } }, "auth_ref": [] }, "evax_SharesIssuedPricePerShare1": { "xbrltype": "perShareItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "SharesIssuedPricePerShare1", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_SharesIssuedPricePerShare1", "terseLabel": "Shares issued, price per share (in dollars per share)", "documentation": "Represents the price per share for shares issued during the period." } } }, "auth_ref": [] }, "ifrs-full_SignificantUnobservableInputEntitysOwnEquityInstruments": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantUnobservableInputEntitysOwnEquityInstruments", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Unobservable input" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of entity's own equity instruments." } } }, "auth_ref": [ "r72" ] }, "evax_Statement1LineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "Statement1LineItems", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-1-general-company-information", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-11-commitments-and-contingencies", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.evaxion-biotech.com/20250630/role/statement-note-4-significant-accounting-judgements-estimates-and-assumptions", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-tables", "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Statement Line Items [Line Items]" } } }, "auth_ref": [] }, "evax_Statement1Table": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "Statement1Table", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-1-general-company-information", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-11-commitments-and-contingencies", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period", "http://www.evaxion-biotech.com/20250630/role/statement-note-12-events-after-the-reporting-period-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.evaxion-biotech.com/20250630/role/statement-note-4-significant-accounting-judgements-estimates-and-assumptions", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue", "http://www.evaxion-biotech.com/20250630/role/statement-note-5-revenue-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-schedule-of-borrowings-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-tables", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-9-financial-income-and-expenses-tables", "http://www.evaxion-biotech.com/20250630/role/statement-significant-accounting-policies-policies", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-cash-flows", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-changes-in-equity-deficit", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-comprehensive-loss", "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Statement Table [Table]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "evax_The2025InvestorWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "The2025InvestorWarrantsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details" ], "lang": { "en-us": { "role": { "label": "The 2025 investor warrants [Member]", "documentation": "represents the 2025 investor warrants." } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-unaudited-condensed-consolidated-interim-statements-of-financial-position" ], "lang": { "en-us": { "role": { "label": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r115", "r139" ] }, "ifrs-full_TypesOfInterestRatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfInterestRatesAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Types of interest rates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r148" ] }, "ifrs-full_TypesOfInterestRatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfInterestRatesDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Types of interest rates [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r88" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters", "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r88" ] }, "evax_UnitsIssuedNumberOfAdsPerUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "UnitsIssuedNumberOfAdsPerUnit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_UnitsIssuedNumberOfAdsPerUnit", "terseLabel": "Units issued, number of ADs per unit (in shares)", "documentation": "the number of ADs per unit of units issued." } } }, "auth_ref": [] }, "evax_UnitsIssuedNumberOfWarrantsPerUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "UnitsIssuedNumberOfWarrantsPerUnit", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_UnitsIssuedNumberOfWarrantsPerUnit", "terseLabel": "Units issued, number of warrants per unit (in shares)", "documentation": "The number of warrants per unit of units issued." } } }, "auth_ref": [] }, "evax_UnitsIssuedOfferingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "UnitsIssuedOfferingPrice", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_UnitsIssuedOfferingPrice", "terseLabel": "Units issued, offering price (in dollars per share)", "documentation": "Per unit price of units issued." } } }, "auth_ref": [] }, "evax_UnitsIssuedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "UnitsIssuedShares", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-10-capital-structure-and-financial-matters-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-2-liquidity-and-going-concern-assessment-details-textual" ], "lang": { "en-us": { "role": { "label": "evax_UnitsIssuedShares", "terseLabel": "Units issued, shares (in shares)", "documentation": "The number of shares of units issued." } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r72", "r146" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r72", "r146" ] }, "evax_WarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "WarrantLiabilitiesMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management", "http://www.evaxion-biotech.com/20250630/role/statement-note-6-financial-instruments-and-risk-management-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrant liabilities [member]", "documentation": "Relating to warrant liabilities." } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-compensation-warrant-assumptions-details", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-details-textual", "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r143" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable, weighted average exercise price (in dollars per share)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Warrants forfeited, weighted average exercise price (in dollars per share)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "Warrants granted, weighted average exercise price (in dollars per share)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "periodEndLabel": "Warrants outstanding, weighted average exercise price (in dollars per share)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-8-sharebased-payments-warrant-activity-details" ], "lang": { "en-us": { "role": { "label": "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "periodStartLabel": "Warrants granted, weighted average exercise price (in dollars per share)" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r85", "r86" ] }, "ifrs-full_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageMember", "presentation": [ "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings", "http://www.evaxion-biotech.com/20250630/role/statement-note-7-borrowings-details-textual" ], "lang": { "en-us": { "role": { "label": "Weighted average [member]" } }, "en": { "role": { "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average." } } }, "auth_ref": [ "r78", "r83", "r128", "r129", "r149" ] }, "evax_statement-statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-10-capital-structure-and-financial-matters-schedule-of-share-capital-details", "lang": { "en-us": { "role": { "label": "Note 10 - Capital Structure and Financial Matters - Schedule of Share Capital (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-10-capital-structure-and-financial-matters-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-10-capital-structure-and-financial-matters-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Capital Structure and Financial Matters" } } }, "auth_ref": [] }, "evax_statement-statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-6-financial-instruments-and-risk-management-disclosure-of-fair-value-measurements-of-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 6 - Financial Instruments and Risk Management - Disclosure of Fair Value Measurements of Liabilities (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-6-financial-instruments-and-risk-management-schedule-of-warrant-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 6 - Financial Instruments and Risk Management - Schedule of Warrant Liabilities (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-6-financial-instruments-and-risk-management-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-6-financial-instruments-and-risk-management-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Financial Instruments and Risk Management" } } }, "auth_ref": [] }, "evax_statement-statement-note-7-borrowings-schedule-of-borrowings-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-7-borrowings-schedule-of-borrowings-details", "lang": { "en-us": { "role": { "label": "Note 7 - Borrowings - Schedule of Borrowings (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-7-borrowings-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-7-borrowings-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Borrowings" } } }, "auth_ref": [] }, "evax_statement-statement-note-8-sharebased-compensation-warrant-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-8-sharebased-compensation-warrant-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 8 - Share-based Compensation - Warrant Assumptions (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-8-sharebased-payments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-8-sharebased-payments-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Share-based Payments" } } }, "auth_ref": [] }, "evax_statement-statement-note-8-sharebased-payments-warrant-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-8-sharebased-payments-warrant-activity-details", "lang": { "en-us": { "role": { "label": "Note 8 - Share-based Payments - Warrant Activity (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-9-financial-income-and-expenses-components-of-financial-income-and-expenses-details", "lang": { "en-us": { "role": { "label": "Note 9 - Financial Income and Expenses - Components of Financial Income and Expenses (Details)" } } }, "auth_ref": [] }, "evax_statement-statement-note-9-financial-income-and-expenses-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-note-9-financial-income-and-expenses-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Financial Income and Expenses" } } }, "auth_ref": [] }, "evax_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.evaxion-biotech.com/20240630", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2024-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2024-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2024-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard", "URIDate": "2024-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard", "URIDate": "2024-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2024-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2024-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2024-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2024-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard", "URIDate": "2024-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2024-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2024-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2024-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2024-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2024-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2024-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2024-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2024-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_b&doctype=Standard", "URIDate": "2024-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2024-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard", "URIDate": "2024-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2024-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard", "URIDate": "2024-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2024-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2024-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard", "URIDate": "2024-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2024-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2024-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard", "URIDate": "2024-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2024-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard", "URIDate": "2024-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2024-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard", "URIDate": "2024-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2024-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2024-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2024-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2024-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2024-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2024-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2024-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2024-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2024-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard", "URIDate": "2024-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2024-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2024-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard", "URIDate": "2024-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2024-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard", "URIDate": "2024-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard", "URIDate": "2024-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2024-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2024-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2024-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "a", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a_v&doctype=Standard", "URIDate": "2024-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2024-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2024-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2024-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2024-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2024-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2024-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2024-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2024-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2024-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard", "URIDate": "2024-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2024-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard", "URIDate": "2024-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard", "URIDate": "2024-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard", "URIDate": "2024-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard", "URIDate": "2024-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2024-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2024-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2024-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2024-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2024-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2024-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2024-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2024-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2024-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2024-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2024-03-27" }, "r135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2024-03-27" }, "r136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2024-03-27" }, "r137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard", "URIDate": "2024-03-27" }, "r138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard", "URIDate": "2024-03-27" }, "r140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2024-03-27" }, "r141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard", "URIDate": "2024-03-27" }, "r142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2024-03-27" }, "r143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2024-03-27" }, "r144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard", "URIDate": "2024-03-27" }, "r145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2024-03-27" }, "r147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard", "URIDate": "2024-03-27" }, "r149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" } } }